Raising the Standard in Pulmonary Arterial Hypertension: Contemporary Approaches to Risk-Guided Treatment

May 23 @ 7:00 pm 8:00 pm EDT

Supported By: Actelion, Bayer, Merck & Co., Inc. and United Therapeutics Corporation

Pulmonary arterial hypertension (PAH) is a chronic and life-changing progressive disease, that when left untreated, can lead to heart failure and death.  The field of PAH has rapidly evolved over the past few years, resulting in improved patient outcomes, but are you identifying patients with PAH early and treating them appropriately?  

To raise the standard in managing PAH, our panel of leading experts will take you through a patient case and present you with evidence-based guideline recommended strategies to identify, risk-stratify and treat your patient with PAH.  The latest data on emerging therapeutic targets will also be discussed. Save your spot and join us in person, or virtually, for a CME-certified interactive and engaging learning experience!